Eli Lilly And Company ((LLY)) announced an update on their ongoing clinical study.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Eli Lilly and Company is conducting a clinical study titled A Single-ascending and Multiple-ascending Dose Study of LY3971297 in Healthy Participants and Participants With Obesity and Hypertension and Participants With Decreased Estimated Glomerular Filtration Rate. The study aims to assess the side effects of the LY3971297 injection, administered under the skin, and its pharmacokinetics in healthy and specific patient groups. This research is significant as it explores the safety and bodily processing of LY3971297, potentially leading to new therapeutic options.
The intervention being tested is LY3971297, a drug administered subcutaneously (SC) and intravenously (IV) across different study parts. Its purpose is to evaluate safety and dosage parameters in healthy individuals and those with specific health conditions.
The study design is interventional, utilizing a randomized, parallel model with double masking for participants and investigators. The primary purpose is basic science, focusing on understanding the drug’s effects and safety profile.
The study began on December 7, 2023, with a primary completion date yet to be announced. The estimated completion date is June 23, 2025, which marks the last update. These dates are crucial for tracking the study’s progress and anticipating results.
The market implications of this study update could be significant for Eli Lilly’s stock performance and investor sentiment. Successful outcomes may enhance the company’s portfolio, potentially impacting its market position. Competitors in the pharmaceutical industry will likely monitor these developments closely.
The study is currently recruiting, with further details available on the ClinicalTrials portal.